BRPI0517663A - composição farmacêutica, método para preparar a mesma, produto, e, método para tratar distúrbios cardiovasculares - Google Patents

composição farmacêutica, método para preparar a mesma, produto, e, método para tratar distúrbios cardiovasculares

Info

Publication number
BRPI0517663A
BRPI0517663A BRPI0517663-8A BRPI0517663A BRPI0517663A BR PI0517663 A BRPI0517663 A BR PI0517663A BR PI0517663 A BRPI0517663 A BR PI0517663A BR PI0517663 A BRPI0517663 A BR PI0517663A
Authority
BR
Brazil
Prior art keywords
ramipril
product
pharmaceutical composition
cardiovascular disorders
treating cardiovascular
Prior art date
Application number
BRPI0517663-8A
Other languages
English (en)
Inventor
Edward S Wilson
Kevin H Sills
M Jolly
Martin W Beasley
David P Hause
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BRPI0517663A publication Critical patent/BRPI0517663A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, MéTODO PARA PREPARAR A MESMA, PRODUTO, E, MéTODO PARA TRATAR DISTURBIOS CARDIOVASCULARES. A presente invenção refere-se aos compostos de ramipril com estabilidade melhorada. Mais particularmente, a presente invenção refere-se às composições farmacêuticas compreendendo ramipril que estão estabilizadas contra decomposição em produtos de degradação, a saber, ramipril-diceto-piperazina e ramipril-diácido, durante condições de formulação e de armazenagem. A presente invenção também se refere aos métodos para preparar e aos métodos de manufaturar composições de ramipril estabilizadas.
BRPI0517663-8A 2004-11-05 2005-11-07 composição farmacêutica, método para preparar a mesma, produto, e, método para tratar distúrbios cardiovasculares BRPI0517663A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62527004P 2004-11-05 2004-11-05
PCT/US2005/040430 WO2006052968A2 (en) 2004-11-05 2005-11-07 Stabilized ramipril compositions and methods of making

Publications (1)

Publication Number Publication Date
BRPI0517663A true BRPI0517663A (pt) 2008-10-14

Family

ID=36319833

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0517662-0A BRPI0517662A (pt) 2004-11-05 2005-11-07 partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica
BRPI0517663-8A BRPI0517663A (pt) 2004-11-05 2005-11-07 composição farmacêutica, método para preparar a mesma, produto, e, método para tratar distúrbios cardiovasculares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0517662-0A BRPI0517662A (pt) 2004-11-05 2005-11-07 partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica

Country Status (14)

Country Link
US (2) US20060134213A1 (pt)
EP (2) EP1817007A2 (pt)
JP (2) JP2008519063A (pt)
KR (2) KR20070085754A (pt)
CN (2) CN101098679A (pt)
AU (2) AU2005301989A1 (pt)
BR (2) BRPI0517662A (pt)
CA (2) CA2586547A1 (pt)
IL (2) IL183018A0 (pt)
MX (2) MX2007005377A (pt)
NO (2) NO20072739L (pt)
RU (2) RU2007120817A (pt)
WO (2) WO2006050533A2 (pt)
ZA (2) ZA200704767B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002548A1 (en) * 2003-06-26 2005-01-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
KR20070085754A (ko) * 2004-11-05 2007-08-27 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정화된 라미프릴 조성물 및 제조 방법
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
WO2007056442A1 (en) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
WO2008134047A1 (en) * 2007-04-27 2008-11-06 King Pharmaceuticals Research And Development, Inc. Methods of treating hypertension
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
ITMI20072427A1 (it) * 2007-12-24 2009-06-25 I P S Internat Products & Ser Matrce polimerica polivalente a immediata disgregazione per prodotti solidi per uso orale a rilascio modificato e metodo per la sua preparazione
WO2010030735A2 (en) * 2008-09-11 2010-03-18 Aethos Pharmaceuticals, Inc. Stabilized coating for pharmaceutical formulations
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2790817A1 (en) * 2010-02-24 2011-09-01 Sanofi-Aventis Deutschland Gmbh Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
RU2479310C2 (ru) * 2011-02-09 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения
CN102139109A (zh) * 2011-03-30 2011-08-03 上海蓝药实业有限公司 一种质量稳定的血管紧张素转化酶抑制剂的制剂组合物
WO2013032002A1 (ja) * 2011-08-31 2013-03-07 株式会社 奈良機械製作所 固体粒子の表面改質装置および固体粒子の表面改質方法
US20150094345A1 (en) * 2012-02-17 2015-04-02 Egis Gyogyszergyar Zrt. Pharmaceutical formulation having improved stability
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
HUP1300496A2 (hu) * 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
IL270152B2 (en) * 2017-04-25 2024-10-01 Proteus Digital Health Inc Lisinopril compositions with an ingestible event marker
EP4103158B1 (en) * 2020-02-10 2024-09-04 Adamed Pharma S.A. Composition comprising ramipril and indapamide
KR20240046661A (ko) 2022-10-01 2024-04-09 김성현 높이 조절 노트북

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
LU88621I2 (fr) * 1980-10-23 1995-09-01 Schering Corp Sandopril
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3300316A1 (de) * 1983-01-07 1984-07-12 Hoechst Ag, 6230 Frankfurt Disubstituierte prolinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE3303112A1 (de) * 1983-01-31 1984-08-09 Hoechst Ag, 6230 Frankfurt Verfahren zur racemattrennung optisch aktiver bicyclischer imino-(alpha)-carbonsaeuren
DE3315464A1 (de) * 1983-04-28 1984-10-31 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
DE3333454A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3431541A1 (de) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
DE3639879A1 (de) * 1986-11-21 1988-06-01 Hoechst Ag Verfahren zur herstellung von mono-, bi- und tricyclischen aminosaeuren, zwischenprodukte dieses verfahrens sowie ein verfahren zu deren herstellung
DE3722007A1 (de) * 1987-07-03 1989-01-12 Hoechst Ag Verfahren zur herstellung bicyclischer aminocarbonsaeuren, zwischenprodukte dieses verfahrens und deren verwendung
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
TW197945B (pt) * 1990-11-27 1993-01-11 Hoechst Ag
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
JP2004534812A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US7022527B2 (en) * 2001-09-12 2006-04-04 National Research Council Of Canada Method for the simultaneous and direct determination of serum cholesterol in high and low density lipoproteins using infrared spectroscopy
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
US20030138486A1 (en) * 2001-10-29 2003-07-24 King Pharmaceuticals Research Methods and dosage forms for improving the bioavailability of therapeutic agents
WO2004064809A1 (en) * 2003-01-22 2004-08-05 Sandoz Ag Solid pharmaceutical composition comprising ramipril
WO2005002548A1 (en) * 2003-06-26 2005-01-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
KR20070085754A (ko) * 2004-11-05 2007-08-27 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정화된 라미프릴 조성물 및 제조 방법
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation

Also Published As

Publication number Publication date
KR20070085759A (ko) 2007-08-27
KR20070085754A (ko) 2007-08-27
WO2006050533A3 (en) 2006-09-14
NO20072739L (no) 2007-07-24
WO2006050533A2 (en) 2006-05-11
JP2008519063A (ja) 2008-06-05
EP1824451A2 (en) 2007-08-29
CA2586760A1 (en) 2006-05-18
JP2008519062A (ja) 2008-06-05
US20060159742A1 (en) 2006-07-20
CN101098681A (zh) 2008-01-02
WO2006052968A3 (en) 2006-10-12
WO2006052968A2 (en) 2006-05-18
CA2586547A1 (en) 2006-05-11
RU2007120821A (ru) 2008-12-10
NO20072741L (no) 2007-08-03
ZA200704768B (en) 2008-08-27
IL183017A0 (en) 2007-09-20
US20060134213A1 (en) 2006-06-22
AU2005304664A1 (en) 2006-05-18
RU2007120817A (ru) 2008-12-10
EP1817007A2 (en) 2007-08-15
MX2007005377A (es) 2008-01-11
ZA200704767B (en) 2008-08-27
AU2005301989A1 (en) 2006-05-11
IL183018A0 (en) 2007-09-20
CN101098679A (zh) 2008-01-02
MX2007005373A (es) 2007-08-14
BRPI0517662A (pt) 2008-10-14

Similar Documents

Publication Publication Date Title
BRPI0517663A (pt) composição farmacêutica, método para preparar a mesma, produto, e, método para tratar distúrbios cardiovasculares
NZ600207A (en) Substituted 4-aminocyclohexane derivatives
BRPI0924136B8 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
WO2008089151A3 (en) High dose film compositions and methods of preparation
EP2055314A4 (en) ACTIVATOR WITH A BIOTENSID AS ACTIVE AGENT, MANNOSYLERYTHRITOL LIPID AND METHOD OF MANUFACTURING THEREOF
MX2011012122A (es) Derivados de tiofeno.
WO2013091775A3 (de) Verwendung von cyclohexanolderivaten als antimikrobielle wirkstoffe
WO2009139576A3 (ko) 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
MY142029A (en) Phenoxyacetic acid derivatives
UA89787C2 (ru) Фторгликозидные производные пиразолов, лекарственное средство, которое содержит их, и их применение
MY149622A (en) Pyrazoles as 11-beta-hsd-1
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2009100936A3 (de) Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2015007540A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
IL227565A (en) Salts of hexahydropananthridine preserved in position 5 of the heterocyclic group and pharmaceutical preparations containing them
MX2009006913A (es) Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2010151008A3 (en) Piperazine dithioctate and pharmaceutical composition comprising the same
TW200637817A (en) 5-aminoindole derivatives
IL186513A0 (en) Aminoalkyl - amidomethyl - substituted 2 - (4 - sulphonylamino) - 3 - hydroxy - 3, 4 - dihydro - 2h - cromen - 6-yl derivatives and their use as potassium channel blockers
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
WO2007002128A3 (en) Compositions comprising and processes for producing inorganic salts of hop acids

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]